Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)

Market Cap	9.87B
Revenue (ttm)	16.21B
Net Income (ttm)	665.03M
Shares Out	2.52B
EPS (ttm)	0.26
PE Ratio	15.03
Forward PE	13.52
Dividend	n/a
Ex-Dividend Date	n/a

Volume	43,279,439
Average Volume	67,930,337
Open	3.900
Previous Close	3.910
Day's Range	3.870 - 3.920
52-Week Range	2.540 - 4.970
Beta	0.27
RSI	60.22
Earnings Date	Aug 22, 2025

About SHA:600664

Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, anti-virus and anti-infection, cerebrovascular, and cardiovascular diseases, as well as mineral and nutritional supplements, Chinese medicines, and antibiotics. It also provides calcium ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1991
• Employees: 10,180
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600664

Financial Performance

In 2024, SHA:600664's revenue was 16.18 billion, an increase of 4.65% compared to the previous year's 15.46 billion. Earnings were 628.85 million, an increase of 59.10%.